These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 28835336)
1. Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease. White MM; Geraghty P; Hayes E; Cox S; Leitch W; Alfawaz B; Lavelle GM; McElvaney OJ; Flannery R; Keenan J; Meleady P; Henry M; Clynes M; Gunaratnam C; McElvaney NG; Reeves EP EBioMedicine; 2017 Sep; 23():173-184. PubMed ID: 28835336 [TBL] [Abstract][Full Text] [Related]
2. Alpha-1 Antitrypsin Therapy Modifies Neutrophil Adhesion in Patients with Obstructive Lung Disease. McEnery T; White MM; Gogoi D; Coleman O; Bergin D; Jundi B; Flannery R; Alsaif FAT; Landers SA; Casey M; Dunlea D; Meleady P; McElvaney NG; Reeves EP Am J Respir Cell Mol Biol; 2022 Jul; 67(1):76-88. PubMed ID: 35507773 [TBL] [Abstract][Full Text] [Related]
3. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. Pohl K; Hayes E; Keenan J; Henry M; Meleady P; Molloy K; Jundi B; Bergin DA; McCarthy C; McElvaney OJ; White MM; Clynes M; Reeves EP; McElvaney NG Blood; 2014 Aug; 124(7):999-1009. PubMed ID: 24934256 [TBL] [Abstract][Full Text] [Related]
4. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
5. Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Tirkos S; Newbigging S; Nguyen V; Keet M; Ackerley C; Kent G; Rozmahel RF Respir Res; 2006 Mar; 7(1):51. PubMed ID: 16571124 [TBL] [Abstract][Full Text] [Related]
6. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833 [TBL] [Abstract][Full Text] [Related]
7. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment. Edgeworth D; Keating D; Ellis M; Button B; Williams E; Clark D; Tierney A; Heritier S; Kotsimbos T; Wilson J Clin Sci (Lond); 2017 Aug; 131(15):2037-2045. PubMed ID: 28611235 [TBL] [Abstract][Full Text] [Related]
8. Neutrophil glutamine deficiency in relation to genotype in children with cystic fibrosis. D'Eufemia P; Finocchiaro R; Celli M; Tote J; Ferrucci V; Zambrano A; Troiani P; Quattrucci S Pediatr Res; 2006 Jan; 59(1):13-6. PubMed ID: 16327011 [TBL] [Abstract][Full Text] [Related]
9. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
10. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. Bodas M; Mazur S; Min T; Vij N Respir Res; 2018 Jan; 19(1):2. PubMed ID: 29301535 [TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
17. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599 [TBL] [Abstract][Full Text] [Related]
18. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666 [TBL] [Abstract][Full Text] [Related]
19. Iron Homeostasis and Inflammatory Status in Mice Deficient for the Cystic Fibrosis Transmembrane Regulator. Deschemin JC; Allouche S; Brouillard F; Vaulont S PLoS One; 2015; 10(12):e0145685. PubMed ID: 26709821 [TBL] [Abstract][Full Text] [Related]
20. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]